Role of urokinase plasminogen activator receptor in gastric cancer: a potential therapeutic target.

Abstract

Recent advancements in cancer research have led to major breakthroughs; however, the impact on overall cancer-related death rate remains unacceptable. Thus, further insights into tumor markers and subsequent development of targeted therapies are urgently needed. For decades the urokinase plasminogen activator (uPA) system has been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells. Intervention with this proteolysis by targeting of uPA receptor (uPAR) has been proposed to represent a novel approach for inhibiting tumor progression. Recent data have provided new insights into the role of uPAR in gastric cancer progression. In addition to mediating proteolysis, this receptor also appears to mediate cell signaling, proliferation, and survival, and these observations have revealed novel ways to target uPAR. In this review, we discuss uPAR expression in gastric cancer, the relationship between uPAR and Helicobacter pylori, and recent insights into uPAR-signaling mechanisms. The role of uPAR as a cancer target in gastric cancer is also summarized.

• Authors: Ying-Yu Ma, Hou-Quan Tao
• Journal: Cancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 27 Issue 5 Pg. 285-90 (Jun 2012) ISSN: 1557-8852 [Electronic] United States
• PMID: 22702495 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Receptors, Urokinase Plasminogen Activator

Topics

• Humans
• Molecular Targeted Therapy
• Receptors, Urokinase Plasminogen Activator (metabolism)
• Stomach Neoplasms (drug therapy, metabolism, pathology)